New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy

Home > Science Hub > New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Back to the list

April 11, 2024

You might also be interested by

Videos

Chats with our Scientific Advisory Board: Rupert Vessey, PhD with Christopher Ung on Drug Development

July 21, 2026

More info

Videos

Chats with our Scientific Advisory Board: Carl June, MD with Christopher Ung on Immunotherapies

July 21, 2026

More info

Videos

Chats with our Scientific Advisory Board: George Demetri, MD and Charles Sawyers, MD with Christopher Ung on Immunotherapies

July 21, 2026

More info

Press Releases

CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development

July 15, 2026

More info